you, that And schedule of to drug assuring will quarter in application fourth XXXX. the resubmit new the on everyone. afternoon NDA I Thank start you by good Khoso. we remain or
have We resolve CMO. as manufacturing to identified a or FDA diligently deficiencies by facility to continued third-party work
As study Response we CorMedix. Complete or the by I have successfully explained have previously, Letter the sent manual completed and FDA extraction by the to required FDA CRL
CMO quarter and collaboratively of with generation CorMedix of NDA by NDA. as the of and addressed to Also, are The volumes. have previously, The ensure can facility withdrawn of filling qualification consistently manufacturing the DEFENCATH to communicated CMC data addressing volume the in additional the deficiencies concerns working DEFENCATH FDA that the the to the deficiencies We approval need are required to we for validation done action CMO and appropriately. from have post-application labeled qualification resolution XXXX. the demonstrated consultants The for the of with teams by the engaged be ensure that process. resubmit closely CorMedix we at the and with identified the process explained of be them the the documentation FDA CMC we validations regulatory CMO sent working facility in fourth process to letter has to are by manufacturing subsequent required the and are vial satisfactorily
also actions may that the address corrective all informed FDA to during the to FDA the be manufacturing actions NDA. be of FDA CorMedix the an complete informed deficiencies to facility the need manufacturing facility resubmission verified facility the evaluation submitted of DEFENCATH will has of NDA. the to resubmission us As onsite by at CMO. the and has be that of previously deficiencies the to subsequent described, CMO corrections Corrective time of
may in foreign inspections and you pandemic will announced know, result to in access in-person patient of have questioned to As of drugs. COVID-XX foreign impact need industry mission for only delayed would critical the decisions continue the inspections facilities in conducted delays approval Congress impede providing May, FDA of drug and be XXXX. that facilities the inspections on that
inspection, for is the inspections CMO is or for prepared for goal to FDA documentation to intend by support our convince manufacturing that to and submit DEFENCATH. we operation to be for While be the data, the appropriate need the in-person remote facility an marketing a ready evaluation interactive a pre-approval commercial may sufficient that an FDA to it interactive remote conduct FDA. for can evaluation application. assess decide to Without
of We interactive determine the uses agency a are to is criteria aware inspection appropriate. not when that remote
financial infections. catheter to As travel of I in bloodstream to life to call will results over cover to hope cash DEFENCATH Thank the and threatening option turn Matt? reducing be for manufacturing, due the and by address to unmet DEFENCATH remain guidance. need restrictions delays recognized when the now the avoid assessing that the you Matt used medical pandemic, agency the potential we has will this FDA related
